How can we optimise inhaled beta2 agonist dose as 'reliever' medicine for qheezy pre-school children?
Trial Acronym: OpSal
Description
Wheezing is a common problem in young children. Many young children have repeated wheezy episodes, and share characteristics with older children who have asthma. Like them, they are often treated with inhaled salbutamol (a "reliever" beta2 agonist drug). However, in the younger children it is difficult to make a definite diagnosis of asthma, and there is much less consensus about treatment.
The study aims to define the correct dose range of salbutamol that produces an adequate response in the vast majority of young children between 2.5 y and 6 y 11 m, who have a history of recurrent wheeze, using special lung function tests (Rint tests) at a single visit.
Study design: Phase IV, randomised, controlled, observer-blinded single-centre trial with four parallel groups
Trial status: Closed to recruitment
Chief Investigator: Prof Somnath Mukhopadhyay >
Start date: November 2014
End date: June 2019
Recruitment target: 156
Summary of study results: n/a
Patient Information Sheet
Download the Patient information sheet >
For further information contact:
E: OpSal@bsuh.nhs.uk
T: 01273 696955 / x2408/2514